Jacobs Levy Equity Management
BBNX

Jacobs Levy Equity Management’s Beta Bionics BBNX Stock Holding History

Jacobs Levy Equity Management’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$358K Sell
22,843
-91,876
-80% -$1.09M ﹤0.01% 868
2026
Q1 		$1.15M Buy
114,719
+77,345
+207% +$1.14M ﹤0.01% 684
2025
Q4 		$1.14M Sell
37,374
-1,617
-4% -$43.2K ﹤0.01% 661
2025
Q3 		$775K Buy
+38,991
New +$685K ﹤0.01% 763

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Jacobs Levy Equity Management's BBNX Position: Q2 2026 in Review

Jacobs Levy Equity Management reduced its Beta Bionics (BBNX) stake by 80% in Q2 2026, selling an estimated $1.09M and leaving 22,843 shares worth $358K. The position accounts for ﹤0.01% of the portfolio, ranked #868.

Jacobs Levy Equity Management first reported a position in BBNX in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.15M in Q1 2026. 134 funds tracked by Wall St. Rank hold BBNX as of Q2 2026.

  • Jacobs Levy Equity Management held 22,843 shares of Beta Bionics worth $358K as of Q2 2026.
  • Jacobs Levy Equity Management sold 91,876 Beta Bionics shares in Q2 2026, an estimated $1.09M.
  • Beta Bionics made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #868 holding.
  • Jacobs Levy Equity Management first reported a position in Beta Bionics in Q3 2025 and has held it in 4 quarters since.
  • Jacobs Levy Equity Management's Beta Bionics position peaked at $1.15M in Q1 2026.
  • 134 funds tracked by Wall St. Rank held Beta Bionics as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.